Type 2 diabetes, in particular, has seen a continuous increase in prevalence, driven by lifestyle shifts and population aging, especially in Westernized societies, where these factors contribute to rising obesity rates
NEW YORK August 4, 2025 Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, today announced the launch of the Noom Microdose GLP-1 Rx Program, a groundbreaking offering designed to unlock weight loss and long-term health benefits while minimizing side effects through personalized microdoses of GLP-1 medication, when clinically appropriate
J Biol Chem 2006
Low levels of this vitamin can cause anemia, which might trigger tiredness or shortness of breath
Cost $1,000 per month in the US without insurance
In the United States, semaglutide generics are not expected until after patent expiration around 2031-2033 or later